| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 102.9 | 83.0 |
| Net income | -4.1 | -0.5 |
| EPS (diluted, $ a share) | $-0.13 | $-0.02 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +23.9% |
|---|---|
| Operating margin | -2.7% |
10-Q filed with the SEC, NASDAQ: CSTL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Castle Biosciences Inc: key numbers
- Share price
- $32.75Close, Nov 16
- Market cap
- $1.01B
- Shares outstanding
- 30.82MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Castle Biosciences Inc
All →Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $112K of Stock
Tobin W. Juvenal, Chief Commercial Officer, sold 3,195 shares of Castle Biosciences Inc at $35.07 a share, worth $112K in total on Nov 11, 2026. Shares held after the trade: 32,737 (-8.9%).
- Value
- $112K
- Shares
- 3,195
- Price
- $35.07
- Role
- Chief Commercial Officer
- Holding change
- -8.9%
- Trade date
- Nov 11, 2026
Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $207K of Stock
Tobin W. Juvenal, Chief Commercial Officer, sold 6,116 shares of Castle Biosciences Inc at $32.67 to $35.04 a share (average $33.77) in 2 transactions, worth $207K in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 32,737 (-8.0%).
- Value
- $207K
- Shares
- 6,116
- Average price
- $33.77
- Role
- Chief Commercial Officer
- Holding change
- -8.0%
- Trade date
- Nov 9, 2026 to Nov 11, 2026
Castle Biosciences Earnings Call: Key Takeaways
Castle Biosciences delivered a strong Q3 2026 beat, raising full-year revenue guidance by $20 million driven by 47% volume growth in TissueCypher.
- Call
- Nov 5, 2026, 4:30 PM ET
Castle Biosciences Financial Results
Castle Biosciences reported Q3 2026 revenue of $102.9 million, a 24% increase year-over-year, driven by strong volume growth in its TissueCypher test. The company raised its full-year 2026 revenue guidance to a range of $385-395 million and reported a net loss of $4.1 million for the quarter.
- Term
- Q3 2026
“Our team delivered another strong quarter, reflecting consistent execution across our portfolio. TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025.”
Derek Maetzold, president and chief executive officer of Castle Biosciences
Castle Biosciences Pres. & Chief Exec. Officer Derek J. Maetzold Sells $523K of Stock
Derek J. Maetzold, Pres. & Chief Exec. Officer, sold 14,496 shares of Castle Biosciences Inc at $36.01 to $36.81 a share (average $36.10) in 6 transactions, worth $523K in total on Nov 2, 2026. Shares held after the trade: 1,396 (-18.9%).
- Value
- $523K
- Shares
- 14,496
- Average price
- $36.10
- Role
- Pres. & Chief Exec. Officer
- Holding change
- -18.9%
- Trade date
- Nov 2, 2026
Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Sells $240K of Stock
Tobin W. Juvenal, Chief Commercial Officer, sold 6,578 shares of Castle Biosciences Inc at $35.58 to $36.62 a share (average $36.42) in 2 transactions, worth $240K in total on Oct 28, 2026. Shares held after the trade: 38,853 (-12.1%).
- Value
- $240K
- Shares
- 6,578
- Average price
- $36.42
- Role
- Chief Commercial Officer
- Holding change
- -12.1%
- Trade date
- Oct 28, 2026